PHAT PE Ratio & Valuation,Is PHAT Overvalued

PHAT Relative Valuation

PHAT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PHAT is overvalued; if below, it's undervalued.

Historical Valuation

Phathom Pharmaceuticals Inc (PHAT) is now in the Overvalued zone, suggesting that its current forward PS ratio of 3.72 is considered Overvalued compared with the five-year average of -4.10. The fair price of Phathom Pharmaceuticals Inc (PHAT) is between 8.08 to 13.12 according to relative valuation methord. Compared to the current price of 14.59 USD , Phathom Pharmaceuticals Inc is Overvalued By 11.19%.

Relative Value

Fair Zone

8.08-13.12

Current Price：14.59

11.19%

Overvalued

-11.50

144.07

EV/EBITDA

Phathom Pharmaceuticals Inc. (PHAT) has a current EV/EBITDA of 144.07. The 5-year average EV/EBITDA is 1.54. The thresholds are as follows: Strongly Undervalued below -56.54, Undervalued between -56.54 and -27.50, Fairly Valued between 30.58 and -27.50, Overvalued between 30.58 and 59.61, and Strongly Overvalued above 59.61. The current Forward EV/EBITDA of 144.07 falls within the Strongly Overvalued range.

-79.80

EV/EBIT

Phathom Pharmaceuticals Inc. (PHAT) has a current EV/EBIT of -79.80. The 5-year average EV/EBIT is -7.48. The thresholds are as follows: Strongly Undervalued below -38.77, Undervalued between -38.77 and -23.12, Fairly Valued between 8.16 and -23.12, Overvalued between 8.16 and 23.80, and Strongly Overvalued above 23.80. The current Forward EV/EBIT of -79.80 falls within the Strongly Undervalued range.

3.72

Phathom Pharmaceuticals Inc. (PHAT) has a current PS of 3.72. The 5-year average PS is 119.46. The thresholds are as follows: Strongly Undervalued below -326.24, Undervalued between -326.24 and -103.39, Fairly Valued between 342.31 and -103.39, Overvalued between 342.31 and 565.16, and Strongly Overvalued above 565.16. The current Forward PS of 3.72 falls within the Historic Trend Line -Fairly Valued range.

-21.86

P/OCF

Phathom Pharmaceuticals Inc. (PHAT) has a current P/OCF of -21.86. The 5-year average P/OCF is -4.49. The thresholds are as follows: Strongly Undervalued below -12.68, Undervalued between -12.68 and -8.59, Fairly Valued between -0.39 and -8.59, Overvalued between -0.39 and 3.71, and Strongly Overvalued above 3.71. The current Forward P/OCF of -21.86 falls within the Strongly Undervalued range.

-21.81

P/FCF

Phathom Pharmaceuticals Inc. (PHAT) has a current P/FCF of -21.81. The 5-year average P/FCF is -5.71. The thresholds are as follows: Strongly Undervalued below -18.39, Undervalued between -18.39 and -12.05, Fairly Valued between 0.63 and -12.05, Overvalued between 0.63 and 6.97, and Strongly Overvalued above 6.97. The current Forward P/FCF of -21.81 falls within the Strongly Undervalued range.

Phathom Pharmaceuticals Inc (PHAT) has a current Price-to-Book (P/B) ratio of -2.45. Compared to its 3-year average P/B ratio of -1.67 , the current P/B ratio is approximately 46.43% higher. Relative to its 5-year average P/B ratio of -2.11, the current P/B ratio is about 15.87% higher. Phathom Pharmaceuticals Inc (PHAT) has a Forward Free Cash Flow (FCF) yield of approximately -22.22%. Compared to its 3-year average FCF yield of -36.99%, the current FCF yield is approximately -39.91% lower. Relative to its 5-year average FCF yield of -31.64% , the current FCF yield is about -29.75% lower.

-2.47

P/B

Median3y

-1.67

Median5y

-2.11

-22.22

FCF Yield

Median3y

-36.99

Median5y

-31.64

Competitors Valuation Multiple

The average P/S ratio for PHAT's competitors is 0.00, providing a benchmark for relative valuation. Phathom Pharmaceuticals Inc Corp (PHAT) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 202.74%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of PHAT increased by 80.91% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 16.35M to 49.50M.

The secondary factor is the P/E Change, contributed -33.40%to the performance.

Overall, the performance of PHAT in the past 1 year is driven by Revenue Growth. Which is more sustainable.

202.74%

16.35M → 49.50M

Revenue Growth

-88.43%

-523.34 → -60.55

Margin Expansion

-33.40%

-5.81 → -3.87

P/E Change

80.91%

8.12 → 14.69

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Phathom Pharmaceuticals Inc (PHAT) currently overvalued or undervalued?

What is Phathom Pharmaceuticals Inc (PHAT) fair value?

PHAT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Phathom Pharmaceuticals Inc (PHAT) is between 8.08 to 13.12 according to relative valuation methord.

How does PHAT's valuation metrics compare to the industry average?

What is the current P/B ratio for Phathom Pharmaceuticals Inc (PHAT) as of Dec 16 2025?

As of Dec 16 2025, Phathom Pharmaceuticals Inc (PHAT) has a P/B ratio of -2.45. This indicates that the market values PHAT at -2.45 times its book value.

What is the current FCF Yield for Phathom Pharmaceuticals Inc (PHAT) as of Dec 16 2025?

As of Dec 16 2025, Phathom Pharmaceuticals Inc (PHAT) has a FCF Yield of -22.22%. This means that for every dollar of Phathom Pharmaceuticals Inc’s market capitalization, the company generates -22.22 cents in free cash flow.

What is the current Forward P/E ratio for Phathom Pharmaceuticals Inc (PHAT) as of Dec 16 2025?

As of Dec 16 2025, Phathom Pharmaceuticals Inc (PHAT) has a Forward P/E ratio of -11.38. This means the market is willing to pay $-11.38 for every dollar of Phathom Pharmaceuticals Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Phathom Pharmaceuticals Inc (PHAT) as of Dec 16 2025?

As of Dec 16 2025, Phathom Pharmaceuticals Inc (PHAT) has a Forward P/S ratio of 3.72. This means the market is valuing PHAT at $3.72 for every dollar of expected revenue over the next 12 months.

PHAT Valuation